Viking Therapeutics is a clinical-stage biotech company focused on developing weight-loss therapies. Read why I rate VKTX ...

The recent data from Novo Nordisk’s Phase 3b trials highlighted the potential advantages of Viking’s VK2735 ... Premium journey today. Viking Therapeutics (VKTX) Company Description: Viking ...

Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

CEO Brian Lian highlighted 2024 as an exceptionally busy year, with successful results from four studies, including the Phase 2 VENTURE trial for subcutaneous VK2735, which demonstrated up to 14.7% ...

Viking Therapeutics stock plunged early Thursday on an earnings report that included mostly incremental updates for its ...

Viking's obesity-drug program is progressing well. Now management is thinking about manufacturing tie-ups. Viking Therapeutics Inc ... of its oral obesity drug VK2735, with a data readout expected ...

13-Week Study to Evaluate the Safety and Efficacy of Oral VK2735 Dosed Once Daily SAN DIEGO, Jan. 8, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage ...

As previously reported, Scotiabank analyst George Farmer initiated coverage of Viking Therapeutics (VKTX) with an Outperform rating and $102 ...

In this article, we are going to take a look at where Viking Therapeutics Inc. (NASDAQ ... results from its potential weight loss asset VK2735, which could potentially become a groundbreaking ...

It looks like VK2735 from Viking could compete fiercely with Eli Lilly's tirzepatide. Unfortunately, it's so far behind that it could be somewhat obsolete by the time Viking Therapeutics has a ...

Nearly a year ago, Viking Therapeutics (NASDAQ ... The injectable version of the candidate, tentatively named VK2735, reduced obesity patients' weight by 14.7% after 13 weeks in a relatively ...